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Abstract objectives Since 1985, Malawi has experienced a dual epidemic of HIV and tuberculosis (TB)
which has been moderated recently by the advent of antiretroviral therapy (ART). The aim of this
study was to describe the association over several decades between HIV/AIDS, the scale-up of ART
and TB case notifications.
methods Aggregate data were extracted from annual reports of the National TB Control
Programme, the Ministry of Health HIV Department and the National Statistics Office. ART
coverage was calculated using the total HIV population as denominator (derived from UNAIDS
Spectrum software).
results In 1970, there were no HIV-infected persons but numbers had increased to a maximum of
1.18 million by 2014. HIV prevalence reached a maximum of 10.8% in 2000, thereafter decreasing
to 7.5% by 2014. Numbers alive on ART increased from 2586 in 2003 to 536 527 (coverage 45.3%)
by 2014. In 1985, there were 5286 TB cases which reached a maximum of 28 234 in 2003 and then
decreased to 17 723 by 2014 (37% decline from 2003). There were increases in all types of new TB
between 1998–2003 which then declined by 30% for extrapulmonary TB, by 37% for new smear-
positive PTB and by 50% for smear-negative PTB. Previously treated TB cases reached a maximum
of 3443 in 2003 and then declined by 42% by 2014.
conclusion The rise and fall of TB in Malawi between 1985 and 2014 was strongly associated
with HIV infection and ART scale-up; this has implications for ending the TB epidemic in high HIV–
TB burden countries.
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Introduction
Malawi’s National Tuberculosis (TB) Control Programme
(NTP) was established in 1964, shortly after the country’s
independence. In 1969, a TB control unit was established
at the Ministry of Health’s headquarters, responsible for
coordinating district activities and monitoring TB cases in
the country. There was a gradual increase in new notified
TB cases from 3492 in 1970 to 4115 in 1979 to 5286 in
1985 – an increase of just over 50% during the 15-year
period [1]. In 1984, under guidance from the Interna-
tional Union Against Tuberculosis and Lung Disease, the
country became one of the first to implement what later
became known as the World Health Organization’s
‘DOTS’ framework for TB control [2]. By 1985, this
standardised strategy had been rolled out countrywide
with good TB case detection, high rates of smear-positive
tuberculosis and excellent treatment outcomes.
This was not to last. The first case of AIDS was
reported in Blantyre, southern Malawi, in December
1985, and within 10 years, HIV prevalence in the adult
population had soared to above 10% [3]. The effect of
this HIV epidemic on the Malawi NTP was devastating.
Annual TB case notifications spiralled out of control
increasing to 500% or more of the 1985 figures. Hospi-
tal-based, district-based and national surveys showed
rapidly increasing HIV-TB co-infection rates that rose
from 26% in 1986 to 77% in 1995 [4–8]. Case fatality
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rates soared and treatment success plummeted to below
70% [1].
The advent of antiretroviral therapy (ART) in 2004,
with rapid national scale-up of treatment thereafter,
reaching over 500 000 people living with HIV (PLHIV)
by 2014, started to turn the tide; TB case notification
rates have stabilised and are beginning to fall [9]. Mala-
wi’s comprehensive national recording and reporting sys-
tem for TB, the national epidemiological projections of
HIV prevalence using the Estimation and Projection
package and Spectrum software from UNAIDS [10], and
the excellent recording and reporting of HIV-infected per-
sons on ART, provide an opportunity to review the asso-
ciation between HIV and TB at a national level over a
30-year period. The aim of this study was to describe the
association between HIV/AIDS, the scale-up of ART and
TB case notifications, stratified by type and category of
disease, between 1985 and 2014.
Methods
Study design and setting
This was a retrospective descriptive study using national
aggregate data in Malawi, a poor country in central-
southern Africa with a population of 17 million and an
estimated one million PLHIV. The scale-up of ART
started in 2004, with numbers of patients alive and
retained on treatment being reported quarterly from the
HIV Department, Ministry of Health. PLHIV are cur-
rently eligible for ART if they are pregnant/breast feed-
ing, have WHO clinical stage 3 or 4 disease or a CD4
count below the nationally agreed threshold (this was
≤250 cells/ll up until 2010, ≤350 cells/ll up to 2014 and
≤500 cells/ll thereafter) in accordance with national and
international guidelines [11, 12]. In the first years of
scale-up, first-line treatment was mainly with a fixed-dose
combination of stavudine–lamivudine–nevirapine; from
2011, there has been a gradual change to tenofovir–
lamivudine–efavirenz.
Malawi has had a well-respected ‘DOTS’ national TB
control programme since 1985, with case finding, diagno-
sis, registration, treatment and treatment outcomes fol-
lowing agreed international guidelines [13]. Patients with
TB are classified according to new and previously treated
disease and divided into smear-positive pulmonary TB
(PTB), smear-negative PTB and extra-pulmonary TB
(EPTB) [13]. Patients with previously treated TB are clas-
sified as relapse smear-positive PTB and ‘other’ which
includes smear-positive failure cases, smear-positive treat-
ment after lost-to-follow-up cases and other retreatment
cases with smear-negative or extra-pulmonary disease.
Study population
The study population included estimated annual numbers
of PLHIV in the country from 1970 to 2014, the number
of PLHIV (adults and children) recorded alive and
retained on ART at the end of each year from 2004 to
2014 and all adults and children registered nationally
each year with TB under the Malawi DOTS TB Pro-
gramme from 1985 to 2014.
Data variables and sources of data
Sources of aggregate data were national annual reports
from the National TB Control Programme and HIV
Department, Ministry of Health, Malawi. Given the
change in national ART eligibility criteria during the
study period, ART coverage was calculated using the
total HIV population as the denominator (derived from
national epidemiological projections using the Estimation
and Projection package and Spectrum software from
UNAIDS [10] and based on national population estimates
obtained from the Malawi National Statistics Office).
Annual TB case notifications were tabulated and TB case
rates per 100 000 were derived from national population
estimates. Patients with TB included registered cases,
stratified by new and previously treated disease and types
of TB.
Analysis and statistics
Data were analysed descriptively, and comparisons
between highest and lowest annual numbers of patients
with TB were made with chi-square tests. Levels of signif-
icance were set at 5%.
Ethics approval
Ethics approval for the study was obtained from the
Malawi National Health Science Research Committee.
The Ethics Advisory Group of the Union, Paris, France,
waived the need for further international ethics approval.
As records and reports were used, informed patient con-
sent was not necessary.
Results
Figure 1a,b shows HIV estimates (numbers of persons
infected with HIV and HIV prevalence) and numbers
alive and retained on ART between 1970 and 2014. In
1970, there were no persons infected with HIV but num-
bers increased to 228 by the end of 1971 and increased
to a maximum of 1 184 103 by the end of 2014. HIV
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prevalence increased from zero in 1970 to a maximum of
10.8% in 2000 and thereafter prevalence decreased to
7.5% by 2014. The numbers alive and on ART increased
from 2586 in 2003 to 536 527 by the end of 2014.
Figure 2a–c shows TB case notifications, stratified by
type and category of TB, between 1985 and 2014. In
1985, there were 5286 TB cases registered in the country
which increased to a maximum of 28 234 by 2003
(530% increase from 1985) and then decreased to
17 723 by 2014 (37% decline from 2003) (Figure 2a).
There were increases in all types of new TB from 1985
which reached a maximum of 8765 for new smear-positive
PTB in 1998, a maximum of 6145 for new EPTB in 2001
and a maximum of 11 246 for smear-negative PTB in 2003
(Figure 2b). The numbers then declined to reach 5564 for
new smear-positive PTB in 2014 (37% decline), 4308 for
new EPTB in 2013 (30% decline) and 5589 for new smear-
negative PTB in 2014 (50% decline). The differences in
declines between new EPTB and new smear-negative PTB
compared with new smear-positive PTB were significant.
For categories of TB, new TB cases increased to a max-
imum of 24 791 in 2003 and then declined to 15 720 in
2014 (37% decline) while previously treated TB cases
increased to a maximum of 3443 in 2003 and thereafter
declined to 2003 in 2014 (42% decline) – these differ-
ences in decline were significant. Changes in relapse TB
and ‘other’ categories of previously treated TB are shown
in Figure 2c. The category of ‘other’ TB was only
reported from 2000. Relapse TB cases declined from
1167 in 2004 to 547 in 2014 (53% decline) which was
significantly higher than the decline shown with ‘other
TB’ which was 2393 in 2005 and 1389 in 2012 (34%
decline; P < 0.001).
The correlation between coverage of ART and TB case
notification rates per 100 000 between 2000 and 2014 is
shown in Figure 3. A steady decline in TB case notifica-
tion rates occurred from 2005 when ART coverage was
still below 5% to 2014 when ART coverage was 45.3%.
Discussion
This study shows the rise and fall of TB in Malawi over
the 30-year period from 1985 to 2014. The rise of TB
observed between 1985 and 2003 (for all types and cate-
gories of TB) has been well-documented in many other
sub-Saharan African countries faced with large and
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Figure 1 Estimated HIV trends and
numbers cumulatively on antiretroviral
treatment in Malawi, 1970–2014. (a)
Estimated HIV prevalence. HIV, Human
immunodeficiency virus. (b) Estimated
number of persons with HIV and number
cumulatively recorded as alive and on
antiretroviral treatment. HIV, Human
immunodeficiency virus; ART,
antiretroviral treatment.
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growing HIV epidemics [14]. The start of the continuous
decline in TB case notifications in Malawi began in 2005,
1 year after national scale-up of ART had started. Swazi-
land has also observed and reported a decline in all TB
case notifications in the last few years, although this trend
started later in the ART scale-up phase compared with
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Figure 2 Tuberculosis case notifications
in Malawi, 1970–2014. (a) Number of
new and previously treated tuberculosis
cases registered per annum. TB,
Tuberculosis. (b) Number of new
tuberculosis cases per annum stratified by
type. TB, Tuberculosis; EPTB,
extrapulmonary tuberculosis. (c). Number
of previously treated tuberculosis cases
per annum stratified by relapse and
‘retreatment other’ cases.
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Malawi [15]. Similar to that observed in Malawi, the
decline in cases in Swaziland was particularly noted for
smear-negative PTB. Interestingly, there was no significant
reduction of relapse TB in Swaziland, while a marked
decline for this category of TB was seen in Malawi.
The strengths of this study are the comprehensive
national TB reports extending back to 1985, the well-
accepted use of Spectrum software to derive national
HIV epidemiological projections and the excellent and
well-recognised quality of data of ART scale-up in the
country [16]. However, there were several limitations.
First, although we had projected HIV data from 1970,
we did not use TB data prior to 1985 as this was before
the roll-out of DOTS in the country and we therefore
cannot vouch for the reliability or accuracy of TB case
notifications at that time. Second, the study was depen-
dent on TB case notifications and these may have been
affected by laboratory performance of smear microscopy
over the 30 years as well as the recognised difficulties in
a resource-poor country like Malawi in establishing accu-
rate diagnoses of smear-negative PTB and EPTB [17, 18].
Third, Malawi’s ART programme extends access to treat-
ment to all Malawian and other nationals living in the
country, while the NTP only includes Malawians living
in the country (foreigners are recorded in separate regis-
ters and not reported on). That being the case, foreigners
reportedly account for only 1% of TB cases in one study
[19]. Finally, the increase and decrease in TB case notifi-
cations over the 30 years may have occurred as a result
of other factors such as socio-economic status of the pop-
ulation, the quality of TB diagnosis or isoniazid preven-
tive therapy. However, although there have been plans to
do so, there has been no significant scale-up of isoniazid
preventive therapy over the last decade.
While causality cannot be proven in an ecological study
such as this, the decline in the burden of TB is likely to be
due to the protective effects of ART against TB. A system-
atic review and meta-analysis of 11 studies involving
cohorts of PLHIV from around the world has shown that
ART significantly reduces rates of TB across a broad range
of CD4 strata by a factor of 65%, this being most notice-
able in patients with advanced HIV disease or low CD4
counts [20]. In sub-Saharan Africa, smear-negative PTB is
particularly associated with HIV infection and advanced
immune suppression, and it is with this type of disease in
Malawi that the most marked changes have occurred over
the last 30 years. Recurrent TB is also a feature of HIV co-
infection, with a decline in cases also observed in a rural
district of Malawi several years ago in association with the
scale-up of ART [21]. Recurrent TB may be due to reacti-
vation ofMycobacterium tuberculosis which has not been
cleared by the previous treatment or due to a new infection
with another strain ofMycobacterium tuberculosis as a
result of new exposure and transmission in the commu-
nity. The immune status of the host, and particularly the
CD4 cell count, is crucial for maintaining protection
against TB whether this is due to preventing reactivation
or preventing progression from new infection to active dis-
ease. Given the rationale for how ART works by immune
reconstitution with elevation of CD4 cell counts, the
effects of ART in reducing recurrent TB are therefore not
surprising as over the last 10 years the proportion of HIV-
infected TB patients started on ART at the start of TB
treatment has gradually increased to exceed 80% [14].
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There are a number of important programmatic impli-
cations from this study. First, Malawi needs to continue
with scaling up ART to reach 100% of its HIV-infected
population not only as a means of controlling the HIV
epidemic but also the TB epidemic. The joint United
Nations Programme on HIV/AIDS (UNAIDS) launch of
the new 90-90-90 treatment targets for HIV should pro-
vide countries like Malawi with the necessary impetus to
move in this direction [22]. These targets specify that by
2020, 90% of individuals living with HIV will be diag-
nosed and know their HIV status, 90% of people with
diagnosed HIV infection will receive sustained ART, and
90% of those on ART will be virally suppressed. These
targets are important because they focus on the majority
of PLHIV learning their HIV status and they advocate
for early treatment by indicating that the majority of
those starting ART are alive and retained on therapy
sometime in the future. In this regard, Malawi pioneered
the Option B+ approach in 2011 whereby HIV-infected
women who are pregnant or breastfeeding can start ART
for life regardless of CD4 cell count or WHO clinical
stage [23], and, in line with recent WHO guidance on
when to start ART [24], the country is preparing to start
all HIV-infected people on ART in the near future.
Recent studies have highlighted the TB preventive benefits
of early start of ART, emphasising that delays in ART
initiation when CD4 cell counts have dropped <200 cells/
ll may result in long-term immune dysfunction and per-
sistent increased risk for TB [25, 26].
Second, in terms of TB prevention, ART is not enough
on its own; in high HIV–TB burden settings, the risk of
tuberculosis in HIV–TB-infected individuals on ART
never decreases to a level seen in patients without HIV
infection [27]. Thus, other interventions may be necessary
such as isoniazid preventive therapy. Observational stud-
ies from Brazil [28], South Africa [29] and a trial in Bots-
wana [30], all suggest that sequential or concurrent use
of ART and isoniazid preventive therapy have additive
effects in reducing the risk of active TB. A randomised
placebo-controlled study in South Africa showed that iso-
niazid preventive therapy given for 12 months to PLHIV
and on ART significantly reduced the risk of active TB
by 37% [31], and results from the TEMPRANO study in
Cote d’Ivoire showed similar effects of isoniazid preven-
tive therapy when added to ART [32]. Malawi needs to
take these findings into consideration and think seriously
about the benefits and risks of including isoniazid preven-
tive therapy into its ART scale-up programme.
Third, attention needs to be paid to effective imple-
mentation of currently available strategies and tools for
TB control: prompt and accurate diagnosis, effective
treatment started immediately after diagnosis and good
infection control practices in health facilities and wher-
ever people with HIV and TB congregate [33]. WHO has
launched a post-2015 bold new patient-centred strategy
that if followed by countries could result in elimination
of TB by 2050 [34].
Finally, while this study shows the strong association
between HIV and TB, it is important to note the growing
association and important links between these two com-
municable diseases and non-communicable diseases such
as diabetes mellitus and hypertension [35]. Communica-
ble and non-communicable diseases occur within the
same patient populations, and as we move forward in
2016 to the new era of the Sustainable Development
Goals [36], it will be vital to secure the political and pro-
grammatic commitment at international and national
levels for integrated and effective action to address them.
In conclusion, this paper reports on the rise and fall of
TB in Malawi between 1985 and 2014, notes the strong
association between HIV infection and the scale-up of
ART and highlights ways forward to end the epidemic.
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